aTyr Pharma, Inc.
ATYR
$5.35
$0.408.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 235.00K | 235.00K | 588.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 235.00K | 235.00K | 588.00K |
| Cost of Revenue | 54.23M | 52.82M | 54.37M | 54.90M | 50.41M |
| Gross Profit | -54.23M | -52.82M | -54.14M | -54.66M | -49.82M |
| SG&A Expenses | 15.82M | 14.23M | 13.78M | 13.39M | 12.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.05M | 67.05M | 68.15M | 68.29M | 63.11M |
| Operating Income | -70.05M | -67.05M | -67.91M | -68.05M | -62.53M |
| Income Before Tax | -66.64M | -63.42M | -64.02M | -63.82M | -57.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.64 | -63.42 | -64.02 | -63.82 | -57.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.00K | 4.00K | -1.00K | -1.00K | -1.00K |
| Net Income | -66.64M | -63.41M | -64.02M | -63.82M | -57.90M |
| EBIT | -70.05M | -67.05M | -67.91M | -68.05M | -62.53M |
| EBITDA | -69.36M | -66.35M | -67.21M | -67.35M | -61.82M |
| EPS Basic | -0.80 | -0.81 | -0.87 | -0.94 | -0.91 |
| Normalized Basic EPS | -0.50 | -0.50 | -0.54 | -0.59 | -0.57 |
| EPS Diluted | -0.80 | -0.81 | -0.87 | -0.94 | -0.91 |
| Normalized Diluted EPS | -0.50 | -0.50 | -0.54 | -0.59 | -0.57 |
| Average Basic Shares Outstanding | 335.13M | 317.30M | 296.89M | 273.43M | 255.51M |
| Average Diluted Shares Outstanding | 335.13M | 317.30M | 296.89M | 273.43M | 255.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |